Goldman Sachs Downgrades Lantheus (LNTH) PT to $77 Amid PYLARIFY Pricing Pressure, Slow Alzheimer’s Drug Uptake

Core Insights - Lantheus Holdings Inc. is currently viewed as a value stock, but has faced a downgrade from Goldman Sachs due to pricing pressures and slower uptake of Alzheimer's therapeutics [1][3] - The company reported Q2 2025 sales of $378.05 million, reflecting a year-over-year decline of 4.07% [2] - An exclusive licensing agreement was established with GE HealthCare for the prostate cancer imaging agent PYLARIFY, which will be developed and commercialized in Japan [2][3] - Lantheus's MK-6240 radiodiagnostic has shown promising results in pivotal studies for Alzheimer's disease, confirming its diagnostic capabilities [3][4] Financial Performance - Q2 2025 sales amounted to $378.05 million, marking a 4.07% decrease compared to the previous year [2] - The downgrade from Goldman Sachs included a price target reduction from $110 to $77 [1] Strategic Developments - Lantheus entered into an exclusive licensing agreement with GE HealthCare for PYLARIFY, aimed at enhancing prostate cancer diagnostics in Japan [2] - The company has made advancements in Alzheimer's diagnostics with MK-6240, which met its co-primary endpoints in clinical studies [3]